Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Reiterates Buy on WUXI XDC; Last Yr's Newly Added Projects Beat Forecast
Recommend 4 Positive 10 Negative 2 |
||||
|
||||
|
UBS has published a research report reiterating a Buy rating on WUXI XDC (02268.HK) for its leading position in the bioconjugate CRDMO platform, continuous capacity expansion, and controllable geopolitical risks. The broker's target price was HKD89.5. In 2025, WUXI BIO (02269.HK), WUXI XDC's parent company, added a total of 209 new projects in 2025, among them over 70 came from WuXi XDC, far above the previous guidance of over 60, according to the report. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
